Caretower provides the latest products of McAfee
Intel Corp. (NASDAQ:INTC): McAfee Co., Ltd, the Japanese subsidiary of McAfee, announced that it is to offer McAfee Mobile Security software pre-installed on Sharp’s (SHCAY) Android-based tablet devices. The tablets will target the education sector and will start shipping this month. Sharp users will have access to McAfee Mobile Security free of charge for 30 days, and can then upgrade to a one-year subscription for 2,980 yen including tax. McAfee is a wholly owned subsidiary of Intel (NASDAQ:INTC). The shares closed at $28.11, down $0.05 or 0.18% on the day. They have traded in a 52-week range of $19.16 to $28.28.
Aetna Inc. (NYSE:AET): Both sides arguing about the constitutionality of the healthcare reform law before the Supreme Court are making special efforts to persuade Justice Anthony Kennedy, the court’s swing vote who will determine the fate of the law, according to The New York Times. Kennedy’s “guiding principle” is liberty, and both sides in the case are arguing that their position advances liberty, the newspaper notes. The shares closed at $50.16, up $0.6 or 1.21% on the day. They have traded in a 52-week range of $33.43 to $49.90.
Hitachi (NYSE:HIT): Hitachi (NYSE:HIT) said it will delist its American Depository Receipts from the New York Stock Exchange, noting the ability of foreign investors to trade its shares on the Tokyo Stock Exchange and a desire to cut costs, reported The Nikkei. Hitachi sees applying for delisting in mid-April, with the procedure likely to be completed 10 days later. The shares closed at $64.69, up $0.77 or 1.2% on the day. They have traded in a 52-week range of $46.91 to $64.78.
Liz Claiborne (NYSE:LIZ): Liz Claiborne (NYSE:LIZ) has held talks with private equity firms about going private at an asking price near $20 a share, but the company is not currently contemplating a deal or exploring a sale, according to sources reporting to The Wall Street Journal. The shares closed at $13.36, up $1.53 or 12.93% on the day. They have traded in a 52-week range of $4.02 to $12.74.
Altria Group (NYSE:MO): The U.S. Food and Drug Administration released two separate draft guidance documents to help fight the tobacco epidemic and stop children from using tobacco. The draft guidance documents implement provisions of the Family Smoking Prevention and Tobacco Control Act that will ultimately provide the public with previously unknown information about the chemicals in tobacco products and help prevent misleading marketing about the risks associated with tobacco products. The first document provides guidance on how companies will comply with the requirement to report on the quantities of potentially harmful chemicals in tobacco products. The second document provides guidance to companies that seek to advertise or market a tobacco product as less harmful or associated with reducing the risk of tobacco-related disease. The FDA also issued draft guidance on submitting applications to sell modified risk tobacco products. Modified risk tobacco products are tobacco products that are sold, distributed, or marketed with a claim to reduce harm or the risk of tobacco-related disease. The draft guidance describes scientific studies and analyses an applicant should submit to demonstrate its product will, or is expected to, significantly reduce harm or exposure to individuals, and benefit the health of the population as a whole. The shares closed at $30.87, up $0.28 or 0.92% on the day. They have traded in a 52-week range of $23.20 to $30.91.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com
Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!
Do You Want More Profits? Wall St. Cheat Sheet Premium newsletter subscribers have been crushing the markets with winning stock picks.
Click here now for your FREE trial to our acclaimed flagship newsletter: